# European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)

Source: https://onco.cc/key-papers/paper-eln-apl-sanz-blood-2019/  
OnCo record `paper-eln-apl-sanz-blood-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The expert panel guidance on acute promyelocytic leukaemia covers the emergency first hours, the choice between arsenic-based and chemotherapy-based regimens by risk, differentiation syndrome, and molecular monitoring.

## Summary

Updated recommendations from a European LeukemiaNet expert panel on diagnosis, supportive care for coagulopathy, risk-adapted treatment with all-trans retinoic acid and arsenic trioxide or chemotherapy, management of differentiation syndrome, molecular monitoring and treatment of relapse.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Blood
- Year: 2019
- DOI: 10.1182/blood-2019-01-894980
- Authors: Sanz MA, Sanz MA, Fenaux P, et al.
- What it means: Starting retinoic acid on morphological suspicion, aggressive blood product support and arsenic-based induction for non-high-risk disease all follow from this document.
- Caveats: Oral arsenic and gemtuzumab-based regimens for high-risk disease have evolved since publication.

## Sources

- Blood 2019: https://doi.org/10.1182/blood-2019-01-894980
- PubMed: https://pubmed.ncbi.nlm.nih.gov/30803991/

## Connected records

- cancers: [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/)
- journals: [Blood](https://onco.cc/journals/blood/)

---
JSON: https://onco.cc/api/v1/entities/paper-eln-apl-sanz-blood-2019.json